A national analysis of adults diagnosed with lung cancer has exposed a striking weakness in the United States’ strategy for finding the disease early: many patients who ultimately develop lung cancer do not qualify for screening under current rules, and most do not receive a low-dose scan before their diagnosis. The study, based on the 2024 National Health Interview Survey, found that only about half of adults with lung cancer met the eligibility criteria recommended by the US Preventive Services Task Force (USPSTF) at the time they were diagnosed. Even more unexpectedly, just one-third reported undergoing low-dose computed tomography, or LDCT, before their cancer was found. The findings suggest that the problem is not simply that people fail to use an available test. The rules themselves may overlook substantial numbers of people at risk, while practical and clinical barriers prevent many eligible individuals from being screened.

Lung cancer is the third most commonly diagnosed cancer in the United States and remains the country’s leading cause of cancer-related death. Its danger is closely tied to timing: tumors discovered after they have spread are much harder to treat successfully, whereas earlier-stage disease may be removed surgically or treated with curative intent. LDCT is designed to detect small abnormalities before symptoms appear. Unlike a conventional diagnostic CT scan, which may cover a broader clinical question and use a higher radiation dose, LDCT uses a carefully calibrated, lower amount of radiation to create images of the lungs. Evidence from the National Lung Screening Trial showed that screening high-risk people with LDCT reduced lung-cancer mortality by about 20 percent compared with chest radiography. Yet the test is useful only if people at elevated risk are identified and return for regular examinations, and if suspicious findings are rapidly evaluated without causing unnecessary invasive procedures.

Under the 2021 USPSTF recommendations, adults between 50 and 80 years old should receive annual LDCT if they currently smoke or quit within the previous 15 years and have accumulated at least 20 “pack-years” of smoking. A pack-year represents smoking one pack of cigarettes per day for one year; someone who smoked two packs daily for 10 years, for example, would have 20 pack-years. The 2021 update lowered the minimum age from 55 to 50 and reduced the smoking threshold from 30 to 20 pack-years, expanding the population eligible for screening. The criteria were intended to improve access and address disparities, but they remain largely dependent on age and cumulative smoking exposure. That creates a blind spot for people who develop lung cancer after lighter smoking histories, long periods since quitting, or no history of smoking at all.

Researchers from the University of California, Irvine, retrospectively examined survey responses from 115 adults aged 50 or older who reported a lung-cancer diagnosis within the previous 10 years. After applying the survey’s statistical weights, the group represented an estimated 638,702 US adults. The analysis used smoking histories to determine whether each person would have qualified for LDCT under the 2021 USPSTF rules at the time of diagnosis. Smoking information was incomplete for four participants, or 3.5 percent of the sample, meaning their eligibility could not be determined. Among the remaining 111 people, 58—52.3 percent in the unweighted sample and approximately 52.0 percent after weighting—met the screening criteria. When people who had never smoked were excluded, eligibility rose to 64.4 percent, or about 66.3 percent using weighted estimates. Even that higher figure means that roughly one in three patients with a smoking history would not have qualified under the current rules.

The study also revealed a sharp difference between having received a CT scan at some point and having received a true screening scan before cancer was diagnosed. Overall, 92 of 110 respondents, or 83.6 percent, said they had undergone LDCT at some time. But only 36 people, or 32.7 percent, reported receiving the scan before their lung-cancer diagnosis; the weighted estimate was 29.6 percent. This distinction matters because CT imaging can be ordered for many reasons, including investigating coughing, chest pain, infection, trauma, or another medical condition. It can also be performed to monitor a known cancer. Such scans may reveal a tumor, but they are not equivalent to systematic screening of people without symptoms. The gap between the two figures therefore suggests that a large share of the imaging reported by patients was diagnostic or follow-up care rather than preventive screening.

The analysis found that women had substantially lower odds of meeting eligibility criteria than men. In the adjusted statistical model, the odds ratio for female sex was 0.31, with a 95 percent confidence interval from 0.12 to 0.77. In practical terms, the result reflects the fact that women in the study generally had accumulated fewer pack-years and had stopped smoking longer ago than men. Women also made up a much larger share of patients who had never smoked: 76.2 percent of never-smokers with lung cancer were female, compared with 43.3 percent among participants with a history of smoking. The researchers observed a possible disparity for non-White participants as well, with an odds ratio of 0.35, although the result narrowly missed conventional statistical significance. When never-smokers were removed from the analysis, demographic factors were no longer significantly associated with eligibility, suggesting that smoking patterns—and the higher proportion of women among never-smokers—helped drive the apparent sex difference.

The findings highlight a biological and epidemiological challenge that fixed smoking thresholds cannot fully address. Cigarette smoking remains the dominant preventable cause of lung cancer, but it is not the only pathway to the disease. Some tumors arise in people who never smoked, including groups in which lung cancer among never-smokers appears to be increasing or is already disproportionately common. Asian women who have never smoked, for instance, have been identified in previous research as an emerging population with elevated risk. Other contributors can include secondhand smoke, occupational exposures, radon, air pollution, inherited susceptibility, and chronic lung inflammation. A rule based only on age and pack-years may therefore be efficient for identifying a major high-risk group while still missing individuals whose risk is clinically meaningful but distributed across several factors. The study’s authors argue that the results add to evidence that current criteria do not capture everyone who will eventually develop lung cancer.

Why eligible people fail to complete screening is less clear from the survey. No demographic characteristic examined by the researchers was significantly associated with receiving LDCT before diagnosis. The reasons may lie in a complicated chain of obstacles: clinicians may not identify eligible patients, patients may not understand that screening is recommended before symptoms appear, and health systems may lack the staff or infrastructure to arrange annual scans and follow-up. Cost, insurance coverage, transportation, time away from work, fear of radiation, stigma surrounding smoking, and anxiety about a possible cancer diagnosis can all reduce participation. Primary-care providers may also be uncertain about the detailed eligibility rules or may prioritize other urgent health needs. Screening is not a one-time event but a recurring process, so a program must maintain contact with patients and ensure that abnormal results are tracked. A single missed appointment can break that chain.

The researchers caution that their estimates should not be interpreted as a perfect measure of screening performance. The survey relied on participants’ memories of their smoking histories, the timing of scans, and the type of CT imaging they received. People may not distinguish an LDCT screening examination from a diagnostic CT performed after symptoms developed, which could make screening uptake appear higher than it truly was. Conversely, incomplete recall of smoking may cause some people to be classified incorrectly as ineligible. The study was cross-sectional and used information collected after diagnosis, so it cannot establish why screening did or did not occur. Because only one year of survey data was analyzed, some racial, ethnic, and language groups were represented by very small numbers, preventing reliable comparisons. Demographic and socioeconomic characteristics such as insurance, income, employment, and residence may also have changed between diagnosis and survey completion, limiting the ability to connect them to earlier screening decisions.

Risk-based screening models could offer one possible way forward. Instead of relying on age and pack-years alone, these models estimate an individual’s probability of developing lung cancer using multiple variables, potentially including smoking intensity, time since quitting, chronic obstructive pulmonary disease, family history, body characteristics, socioeconomic conditions, and other clinical factors. Such approaches might identify some people who fall outside the USPSTF thresholds, including those with lower smoking exposure or additional non-smoking risks. But they also introduce new complications: the necessary data may be missing from medical records, risk calculations can be difficult to explain, and adding more inputs may make programs harder to implement consistently. For now, the new analysis points to a two-part public-health emergency. Screening systems must do a better job reaching people who already qualify, while researchers and policymakers must determine whether eligibility rules should evolve beyond smoking and age. Until both problems are addressed, many lung cancers may continue to be discovered only after the window for the simplest and most effective treatment has begun to close.

Subject of Research: Lung cancer screening eligibility and low-dose computed tomography completion among US adults diagnosed with lung cancer

Article Title: Lung cancer screening eligibility and completion among adults diagnosed with lung cancer: retrospective analysis of 2024 National Health Interview Survey

Article References: Zanazanian I, Chieh AYC, Madan A, et al. “Lung cancer screening eligibility and completion among adults diagnosed with lung cancer: retrospective analysis of 2024 National Health Interview Survey.” Cancer Causes & Control 37, article 148 (2026). Original research article

Image Credits: AI Generated

DOI: 10.1007/s10552-026-02229-x

Keywords: lung cancer screening, low-dose CT, USPSTF guidelines, screening eligibility, health disparities, smoking history, early cancer detection, never-smokers

Cancer screening programs are designed to detect the disease in its early stages, a crucial factor that can lead to improved survival rates. However, despite significant advancements in medical technology and understanding of cancer biology, disparities in screening practices exist worldwide. The authors highlight that socioeconomic status, cultural beliefs, and healthcare policies play pivotal roles in shaping these differences. Understanding these factors is essential for developing effective strategies that can mitigate the barriers to cancer screening.

The authors present a poignant illustration of how societal attitudes towards health, illness, and mortality can either hinder or facilitate the acceptance of screening programs. In many developing countries, for instance, prevalent beliefs in alternative medicine may contribute to skepticism regarding conventional cancer screening methods. This skepticism not only affects individual choices but can also ripple throughout communities, leading to a collective resistance to screening initiatives, significantly hindering early detection efforts.

Equally important is the role of education in informing communities about the benefits of early detection. Ghaemi-Amiri and Mostafazadeh-Bora argue that comprehensive education programs that include culturally sensitive information about cancer and its prevention should be at the forefront of public health initiatives. Such educational endeavors are not merely advantageous; they are essential. When patients are well-informed, they are more likely to engage in conversations with healthcare providers about screening, ultimately leading to increased participation in early detection programs.

The financial implications of cancer screening are also crucial to this dialogue. In many parts of the world, the cost associated with screening procedures can prohibit access for low-income populations. The researchers advocate for governmental policies that could subsidize costs or offer free screening services for at-risk populations. By minimizing the economic burden, lower-income individuals could gain increased access to potentially life-saving screenings, thereby improving overall community health outcomes.

In addition, the geographical discrepancies in healthcare infrastructure reflect another challenge. Urban areas often have greater access to advanced medical technologies and specialists compared to rural regions. Here, too, Ghaemi-Amiri and Mostafazadeh-Bora highlight the need for strategic healthcare reforms that address such disparities. Creating mobile screening units that can reach remote areas may serve as a practical solution for communities with limited access to healthcare facilities. Such initiatives could significantly increase screening rates, leading to earlier detection and intervention.

Technological advancements also play a pivotal role in shaping cancer screening practices. The researchers underscore that innovations such as artificial intelligence and machine learning are transforming how cancer screenings are conducted. These technologies promise to enhance the accuracy of screenings and potentially reduce false positives and negatives, thereby increasing patient trust in these processes. However, the authors caution that these technologies must be employed judiciously, as overreliance could lead to disparities in healthcare outcomes, particularly if access to technology is unequal across different demographics.

Another significant aspect discussed is the ethical considerations surrounding cancer screening. In their analysis, Ghaemi-Amiri and Mostafazadeh-Bora note that informed consent is a crucial part of any screening protocol. Patients must be made aware of the potential risks and benefits involved in cancer screening, including the psychological ramifications of a false positive result. Ethical screening practices thus demand transparency and respect for patient autonomy, ensuring that individuals are not unduly pressured into participating without fully understanding the implications.

Furthermore, the writers address the emotional aspects of cancer screening, acknowledging that the journey is often fraught with anxiety for many individuals. The fear of receiving a cancer diagnosis can be paralyzing and may lead many to avoid screening altogether. Therefore, the authors suggest that support systems, including counseling and peer support groups, should be integrated into screening programs to help alleviate this anxiety. Such support not only encourages participation but also assists individuals in processing their emotions regarding the uncertainties of cancer.

In the context of public health, the researchers emphasize the importance of community engagement. They argue that involving community leaders and organizations in the design and implementation of screening initiatives can significantly improve their effectiveness. Tailoring programs to fit the unique cultural and social contexts of communities ensures that they are both relevant and acceptable, fostering a sense of ownership and participation among the members of those communities.

In summary, Ghaemi-Amiri and Mostafazadeh-Bora provide a thorough examination of the complex, multifactorial challenges that impede effective cancer screening in various societies. They illuminate how cultural, socioeconomic, educational, and technological factors intersect to create disparities in health outcomes. Their research calls for collaborative efforts among stakeholders, including policymakers, healthcare providers, and community organizations, to develop and implement comprehensive strategies that prioritize equitable access to cancer screening for all populations.

In conclusion, addressing the debatable and significant factors surrounding cancer screening requires a concerted effort that looks beyond mere medical interventions. It demands a thorough understanding of the intricate social fabric that influences healthcare behaviors. Only through holistic approaches can we hope to overcome barriers and harness the full potential of cancer screening as a tool for saving lives.

Subject of Research: Cancer Screening Challenges
Article Title: Inhibition of big challenge of cancer screening in various societies: what is debatable and significant?
Article References: Ghaemi-Amiri, M., Mostafazadeh-Bora, M. Inhibition of big challenge of cancer screening in various societies: what is debatable and significant?.
J Transl Med 23, 976 (2025). https://doi.org/10.1186/s12967-025-07002-3
Image Credits: AI Generated
DOI: 10.1186/s12967-025-07002-3
Keywords: Cancer, screening, public health, disparities, healthcare access, early detection, cultural factors